Phathom Pharmaceuticals (PHAT)
(Delayed Data from NSDQ)
$9.67 USD
+0.15 (1.52%)
Updated May 13, 2024 04:00 PM ET
After-Market: $9.66 -0.01 (-0.10%) 6:26 PM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
Price, Consensus and EPS Surprise
PHAT 9.67 +0.15(1.52%)
Will PHAT be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for PHAT based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for PHAT
Phathom Pharmaceuticals, Inc. (PHAT) Reports Q1 Loss, Lags Revenue Estimates
Zacks.com featured highlights include Phathom Pharmaceuticals, Universal Stainless & Alloy Products and Arlo Technologies
PHAT: What are Zacks experts saying now?
Zacks Private Portfolio Services
3 Top Breakout Stocks Worth a Buy for Attractive Returns
Does Phathom Pharmaceuticals, Inc. (PHAT) Have the Potential to Rally 81.38% as Wall Street Analysts Expect?
Phathom Pharmaceuticals, Inc. (PHAT) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
Other News for PHAT
Phathom Pharmaceuticals, Inc. (PHAT) Q1 2024 Earnings Call Transcript
Craig-Hallum Remains a Buy on Phathom Pharmaceuticals (PHAT)
The 3 Best Healthcare Stocks to Buy in May 2024
Wall Street Analysts Are Bullish on Top Healthcare Picks
PHAT Stock Earnings: Phathom Pharmaceuticals Misses EPS, Misses Revenue for Q1 2024